CTLA-4 Control over Foxp3 + Regulatory T Cell Function
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Naturally occurring Foxp3+CD4+ regulatory T cells (Tregs) are essential for maintaining immunological self-tolerance and immune homeostasis. Here, we show that a specific deficiency of cytotoxic T lymphocyte antigen 4 (CTLA-4) in Tregs results in spontaneous development of systemic lymphoproliferation, fatal T cell-mediated autoimmune disease, and hyperproduction of immunoglobulin E in mice, and it also produces potent tumor immunity. Treg-specific CTLA-4 deficiency impairs in vivo and in vitro suppressive function of Tregs-in particular, Treg-mediated down-regulation of CD80 and CD86 expression on dendritic cells. Thus, natural Tregs may critically require CTLA-4 to suppress immune responses by affecting the potency of antigen-presenting cells to activate other T cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The central role that CTLA-4 plays in immunological tolerance is exemplified by experiments in mice that lack the CTLA-4 gene globally or specifically in the Forkhead box P3 (FoxP3)+ Treg compartment. These animals develop lymphoproliferative disorders and die at a young age (25, 26).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Indeed, this process is an important mechanism by which Tregs mediate immune suppression on bystander cells (25).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Of note, although CTLA4 blockade was shown to cause selective depletion of intratumoral Tregs through antibody-dependent cell-mediated cytotoxicity (ADCC) in murine models and ex vivo experiments on human tumor samples (24)(25)(26),”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [24]
In the citing paper
“The CTLA-4 regulatory effects mainly temper the activation of CD4+ helper T cells while boosting regulatory T cells (Tregs) (Doyle et al., 2001; Wing et al., 2008), leading to a pro-tumor immunosuppressive phenotype.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Wing et al., 2008
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Self-citationRegulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Self-citationRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,081
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Research works printed but not linked: 1
- 10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x · doi:10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x
Cited by
Items 401–500 of 1,010
The B7:CD28 family and friends: Unraveling coinhibitory interactions
Burke, K. P., Chaudhri, A., Freeman, G. J., & Sharpe, A. H. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.013 · Cited by 155
Vaeth, M., Schliesser, U., Müller, G., Reissig, S., Satoh, K., Tuettenberg, A., Jonuleit, H., Waisman, A., Müller, M. R., Serfling, E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203870109 · Cited by 137
“Nfat1 × Nfat4, B6-Tg (Cd4-cre) 1Cwi/Cwilbcm (European mouse mutant archive, Rome, Italy) and Foxp3-IRES-cre have been described previously (16, 49, 50) (SI Materials and Methods).”
Roles of Regulatory T Cells in Tissue Pathophysiology and Metabolism
Campbell, C., & Rudensky, A. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.010 · Cited by 154
Sun, Y., Tian, T., Gao, J., Liu, X., Hou, H., Cao, R., Li, B., Quan, M., & Guo, L. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.01.014 · Cited by 329
Adeegbe, D. O., Liu, Y., Lizotte, P. H., Kamihara, Y., Aref, A. R., Almonte, C., Dries, R., Li, Y., Liu, S., Wang, X., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1020 · Cited by 149
Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations
Verma, N., Burns, S. O., Walker, L. S. K., & Sansom, D. M. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.12997 · Cited by 160
The clinical promise of immunotherapy in triple-negative breast cancer
Vikas, P., Borcherding, N. C., & Zhang, W. (2018) · Cancer Management and Research · doi:10.2147/cmar.s185176 · Cited by 156
“26,61 Recent research has suggested that depletion of Tregs by anti-CTLA-4 therapy is one of the major reasons leading to therapeutic responses.”
Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types
Oyewole-Said, D., Konduri, V., Vazquez‐Perez, J., Weldon, S. A., Levitt, J. M., & Decker, W. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.608024 · Cited by 154
Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells
Ding, R., Yu, X., Hu, Z., Dong, Y., Huang, H., Zhang, Y., Han, Q., Ni, Z.-Y., Zhao, R., Ye, Y., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.019 · Cited by 157
Resolving the identity myth: Key markers of functional CD4+FoxP3+ regulatory T cells
Chen, X., & Oppenheim, J. J. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.05.018 · Cited by 126
“This molecule is reported to be critically required for the function of Tregs in vivo [44].”
BackgroundBabu, S., Bhat, S. Q., Pavan Kumar, N., Lipira, A. B., Kumar, S., Karthik, C., Kumaraswami, V., & Nutman, T. B. (2009) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000420 · Cited by 134
Cytotoxic T-Lymphocyte–Associated Antigen-4
Salama, A. K. S., & Hodi, F. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2232 · Cited by 149
Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells
Hirakawa, M., Matos, T. R., Liu, H., Koreth, J., Kim, H. T., Paul, N. E., Murase, K., Whangbo, J., Alho, A. C., Nikiforow, S., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89278 · Cited by 151
IL-10-producing T cells and their dual functions
Bedke, T., Muscate, F., Soukou, S., Gagliani, N., & Huber, S. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101335 · Cited by 152
Dutta, S., Ganguly, A., Chatterjee, K., Spada, S., & Mukherjee, S. (2023) · Biology · doi:10.3390/biology12020218 · Cited by 153
Johanns, T. M., Ertelt, J. M., Rowe, J. H., & Way, S. S. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001043 · Cited by 140
“These results are consistent with the recent demonstration that CTLA-4 expression on Foxp3 Tregs is essential for maintaining peripheral tolerance [46,75].”
BackgroundResultBluestone, J. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01019.x · Cited by 119
“In fact, the combination of regulatory cells and suppressive factors, including anti-inflammatory molecules such as indoleamine 2,3-dioxygenase (IDO) and transforming growth factor-b (TGF-b), produced by the tumors themselves provide an ‘immune privileged’ site that mitigates immunity and enhances Treg activity.”
BackgroundInfluentialThe Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer
Jørgensen, N., Persson, G., & Hviid, T. V. F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00911 · Cited by 151
“Much research have been performed on the mechanism of antitumor immunity elicited by CTLA-4 blockade and one study has shown that Treg-specific CTLA-4 deficiency results in downregulation of CD80 and CD86 on DCs leading to loss of immunosuppression (99).”
BackgroundTolerance in the Age of Immunotherapy
Bluestone, J. A., & Anderson, M. S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1911109 · Cited by 150
mTOR Signaling, Tregs and Immune Modulation
Chapman, N. M., & Chi, H. (2014) · Immunotherapy · doi:10.2217/imt.14.84 · Cited by 148
Plitas, G., & Rudensky, A. Y. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033428 · Cited by 148
CTLA-4 and autoimmunity: New insights into the dual regulator of tolerance
Romo‐Tena, J., Gómez‐Martín, D., & Alcocer-Varela, J. C. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.07.002 · Cited by 148
Kalathil, S. G., Lugade, A. A., Pradhan, V., Miller, A., Parameswaran, G. I., Sethi, S., & Thanavala, Y. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201312-2293oc · Cited by 132
Siede, J., Fröhlich, A., Datsi, A., Hegazy, A. N., Varga, D. V., Holecska, V., Saito, H., Nakae, S., & Löhning, M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161507 · Cited by 128
“Additionally, CTLA-4 is crucial for the suppressive function of Tregs [38].”
BackgroundBlimp1 Prevents Methylation of Foxp3 and Loss of Regulatory T Cell Identity at Sites of Inflammation
Garg, G., Muschaweckh, A., Moreno, H., Vasanthakumar, A., Floess, S., Lepennetier, G., Oellinger, R., Zhan, Y., Regen, T., Hiltensperger, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.070 · Cited by 140
“, 2001) (from Jackson Laboratory) or with Foxp3 Cre mice (Wing et al., 2008) obtained on the C57BL/6 background from M.”
BackgroundSuárez-Fueyo, A., Ramos, T., Galán, A., Jimeno, L., Wurtzen, P. A., Marin, A., de Frutos, C., Blanco, C., Carrera, A. C., Barber, D., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.09.043 · Cited by 147
Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy
Chuckran, C. A., Liu, C., Bruno, T. C., Workman, C. J., & Vignali, D. A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000967 · Cited by 147
Protein kinase C-η controls CTLA-4–mediated regulatory T cell function
Kong, K.-F., Fu, G., Zhang, Y., Yokosuka, T., Casas, J., Canonigo-Balancio, A. J., Becart, S., Kim, G., Yates, J. R., Kronenberg, M., et al. (2014) · Nature Immunology · doi:10.1038/ni.2866 · Cited by 136
Robert, C., & Ghiringhelli, F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0028 · Cited by 129
The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy
Lee, J., Lozano‐Ruiz, B., Yang, F. M., Fan, D. D., Shen, L., & González-Navajas, J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625667 · Cited by 147
“It is mainly expressed on CD4 and CD8 T cells upon activation, but is constitutively expressed on Tregs where it contributes to their suppressive function (18).”
BackgroundDeleterious Effect of CTLA4-Ig on a Treg-Dependent Transplant Model
Riella, L. V., Liu, T., Yang, J., Chock, S., Shimizu, T., Mfarrej, B. G., Batal, I., Xiao, X., Sayegh, M. H., & Chandraker, A. K. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03929.x · Cited by 146
“2 ligands, CTLA4-Ig not only interferes with activation of naı̈ve T cells through CD28, but it also affects CTLA4 signaling, which is required for the suppressive function of Tregs (35).”
BackgroundSlc3a2 Mediates Branched-Chain Amino-Acid-Dependent Maintenance of Regulatory T Cells
Ikeda, K., Kinoshita, M., Kayama, H., Nagamori, S., Kongpracha, P., Umemoto, E., Okumura, R., Kurakawa, T., Murakami, M., Mikami, N., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.082 · Cited by 137
“Foxp3-IRES-Cre mice on a C57BL/6J background were generated as described previously (Wing et al., 2008).”
MethodSelf-citationWierz, M., Pierson, S., Guyonnet, L., Viry, E., Lequeux, A., Oudin, A., Niclou, S. P., Ollert, M. W., Berchem, G., Janji, B., et al. (2018) · Blood · doi:10.1182/blood-2017-06-792267 · Cited by 146
“Such phenotype reflects cells with enhanced suppressive capacities.(14,15) In contrast, the density of naive CD44CD62LCD38PD1KLRG1Treg (cluster 41/A) was not altered in AT-TCL1 mice.”
BackgroundImmunotherapy earns its spot in the ranks of cancer therapy
Pardoll, D. M., & Drake, C. G. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112275 · Cited by 146
“…responses, both CTLA-4 and PD-1 (as well as other checkpoint receptors, such as LAG-3) are highly expressed on regulatory T (T reg) cells, and in fact directly promote T reg cell–mediated suppression of effector immune responses (Huang et al., 2004; Wing et al., 2008; Peggs et al., 2009; Figure 1.”
BackgroundT Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints
Mirzaei, R., Sarkar, S., & Yong, V. W. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.11.005 · Cited by 147
Tsai, H.-F., & Hsu, P. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0341-0 · Cited by 145
“Immune checkpoints or coinhibitory receptors have a central role in regulating autoimmunity, and deficiency of CTLA-4 develops profound lymphoproliferation and systemic autoimmune disease [10, 11].”
BackgroundChen, J., Ye, X., Pitmon, E., Lu, M., Wan, J., Jellison, E. R., Adler, A. J., Vella, A. T., & Wang, K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0757-z · Cited by 146
Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
Tang, L., Wang, J., Lin, N., Zhou, Y., He, W., Liu, J., & Ma, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.800879 · Cited by 144
“In addition to the CTLA-4-mediated inhibitory interaction between T cells and APCs, immunosuppressive cytokines produced by regulatory T cells (Treg cells) include IL-10 and TGF-b and also inhibit T-cell activation and proliferation (84, 85).”
BackgroundLiu, D., Liang, S., Ma, K., Meng, Q., Li, X., Wei, J., Zhou, M., Yun, K., Pan, Y., Rao, L., et al. (2024) · Advanced Materials · doi:10.1002/adma.202304845 · Cited by 120
Baksh, K. A., & Weber, J. S. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.015 · Cited by 145
Molecular Mechanisms in Autoimmune Type 1 Diabetes: a Critical Review
Xie, Z., Chang, C., & Zhou, Z. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8422-2 · Cited by 144
“CTLA4 plays a role in producing a negative signal to inhibit T cell activation and has a crucial role in the function of CD4 T regulatory cells [103].”
BackgroundMitsui, J., Nishikawa, H., Muraoka, D., Wang, L., Noguchi, T., Sato, E., Kondo, S., Allison, J. P., Sakaguchi, S., Old, L. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3243 · Cited by 135
Self-citationSolid Tumors Challenges and New Insights of CAR T Cell Engineering
Tahmasebi, S., Elahi, R., & Esmaeilzadeh, A. (2019) · Stem Cell Reviews and Reports · doi:10.1007/s12015-019-09901-7 · Cited by 144
Li, B., Hao, G., Sun, B., Gu, Z., & Xu, Z. P. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909745 · Cited by 143
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 146
“CTLA-4 is a modulator of Tregs (80) and these cells act as gatekeepers for the prevention of autoimmunity.”
BackgroundZappasodi, R., Budhu, S., Hellmann, M. D., Postow, M. A., Senbabaoglu, Y., Manne, S., Gasmi, B., Liu, C., Zhong, H., Li, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.009 · Cited by 142
“CTLA-4 and PD-1 checkpoints are particularly deregulated in tumor-bearing hosts, where chronic ineffective immune responses usually predominate and result in T-cell exhaustion and Treg induction(Wing et al., 2008).”
BackgroundThe soluble isoform of CTLA‐4 as a regulator of T‐cell responses
Ward, F. J., Dahal, L. N., Wijesekera, S. K., Abdul-Jawad, S., Kaewarpai, T., Xu, H., Vickers, M. A., & Barker, R. N. (2013) · European Journal of Immunology · doi:10.1002/eji.201242529 · Cited by 142
Dendritic cells as targets for therapy in rheumatoid arthritis
Khan, S., Greenberg, J. D., & Bhardwaj, N. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.185 · Cited by 127
“Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a negative regulator of T-cell activation that is also expressed on T REG cells”
BackgroundIL-2–dependent adaptive control of NK cell homeostasis
Gasteiger, G., Hemmers, S., Bos, P. D., Sun, J. C., & Rudensky, A. Y. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122571 · Cited by 123
The expanding role of immunotherapy
Martín-Liberal, J., de Olza, M. O., Hierro, C., Gros, A., Rodon, J. A., & Tabernero, J. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.008 · Cited by 142
Kim, G., & Choi, J. (2022) · Molecules and Cells · doi:10.14348/molcells.2022.2056 · Cited by 141
“CTLA-4 negatively regulates T-cell activation and plays an important role in the suppressive function of regulatory T (Treg) cells (Krummel and Allison, 1995; Walunas et al., 1994; Wing et al., 2008).”
BackgroundUnderstanding the CD28/CTLA-4 (CD152) Pathway and Its Implications for Costimulatory Blockade
Gardner, D., Jeffery, L. E., & Sansom, D. M. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12834 · Cited by 121
“This issue has been convincingly demonstrated by recent experiments using Tregs from CTLA-4-deficient mice (28) or conditionally deficient Tregs (29), which reveal CTLA-4 to be critical for Treg function in the prevention of autoimmunity.”
MethodChan, D. V., Gibson, H. M., Aufiero, B. M., Wilson, A. J., Hafner, M. S., Mi, Q.-S., & Wong, H. K. (2014) · Genes & Immunity · doi:10.1038/gene.2013.57 · Cited by 128
Upconversion in photodynamic therapy: plumbing the depths
Hamblin, M. R. (2018) · Dalton Transactions · doi:10.1039/c8dt00087e · Cited by 139
Tanchot, C., Terme, M., Pere, H., Tran, T., Benhamouda, N., Strioga, M., Banissi, C., Galluzzi, L., Kroemer, G., & Tartour, E. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0122-y · Cited by 138
“Of note, Tregs devoid of CTLA-4 have been shown to lose their immunosuppressive activity [26].”
BackgroundOrchestrating immune check-point blockade for cancer immunotherapy in combinations
Perez‐Gracia, J. L., Labiano, S., Rodriguez-Ruiz, M. E., Sanmamed, M. F., & Melero, I. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.002 · Cited by 139
“ctla-4 / mice develop lethal autoimmunity but with a longer latency [20].”
Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment
Dalmazi, G. D., Ippolito, S., Lupi, I., & Caturegli, P. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1701434 · Cited by 138
“Deletion during embryonic life causes autoimmune responses of lower severity, where mice die at about 6 months of age with modest and less prevalent multi-organ lymphocytic infiltration [22]; deletion during adulthood leads, on the contrary, to resistance to autoimmunity, where mice have greater numbers of regulator T…”
BackgroundA conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target
Freeman, Z. T., Nirschl, T. R., Hovelson, D. H., Johnston, R. J., Engelhardt, J. J., Selby, M. J., Kochel, C. M., Lan, R. Y., Zhai, J., Ghasemzadeh, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci128672 · Cited by 124
“CTLA-4 is expressed on Tregs in a variety of settings other than cancer; thus, therapies that are targeted to deplete CTLA-4– expressing Tregs may have unanticipated adverse effects (9).”
BackgroundRole of T cells in graft rejection and transplantation tolerance
Issa, F., Șchiopu, A., & Wood, K. J. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.64 · Cited by 141
An update on regulatory T cells in transplant tolerance and rejection
Li, X. C., & Turka, L. A. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.101 · Cited by 138
“T REG cells also express CTLA-4 on their surface, which can directly engage the peripheral membrane protein B7 on antigen-presenting cells (APCs) to inhibit APC activation via different mechanisms”
BackgroundImmunotherapies for malignant glioma
Boussiotis, V. A., & Charest, A. (2017) · Oncogene · doi:10.1038/s41388-017-0024-z · Cited by 137
“Coinhibitory pathways also regulate the generation and function of thymic-derived Treg and Treg generated at peripheral sites [181, 182].”
BackgroundThe biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Wang, X., Wang, F., Zhong, M., Yarden, Y., & Fu, L. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01200-x · Cited by 139
“Second, more Treg cells would be recruited by the activated PD-1+ Treg cells with high expression of CTLA-4 through restriction of APC activation and access for CD8+T cells (downregulation of the costimulatory molecules CD80/CD86) [43, 44].”
LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy
Sharma, N., Atolagbe, O. T., Ge, Z., & Allison, J. P. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201811 · Cited by 131
Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs
Akimova, T., Ge, G., Golovina, T., Mikheeva, T., Wang, L., Riley, J. L., & Hancock, W. W. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.04.018 · Cited by 131
“These data are consistent with the impaired Treg suppression and development of systemic autoimmunity seen in mice with a selective deficiency of CTLA-4 in their Tregs [48].”
ResultOrgan-Specific and Memory Treg Cells: Specificity, Development, Function, and Maintenance
Gratz, I. K., & Campbell, D. J. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00333 · Cited by 121
“In contrast, Treg-specific deletion of CTLA-4 results in systemic autoimmunity associated with dysregulated activation of T cells in secondary lymphoid tissues and lymhoproliferation (123).”
BackgroundTranscriptional and posttranslational regulation of Th17/Treg balance in health and disease
Zhang, W., Liu, X., Zhu, Y., Liu, X., Gu, Y., Dai, X., & Li, B. (2021) · European Journal of Immunology · doi:10.1002/eji.202048794 · Cited by 137
Regulatory T Cells Interfere with Glutathione Metabolism in Dendritic Cells and T Cells
Yan, Z., Garg, S. K., & Banerjee, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.189944 · Cited by 117
Kong, Y.-C. M., & Flynn, J. C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00206 · Cited by 124
“Thus, targeting CTLA-4, a T cell regulatory molecule, impacts on its two primary functions in the immune network: (1) Its upregulation during a T cell-mediated response serves as a negative regulator by engaging the B7 family costimulatory molecules on antigen-presenting cells with higher avidity than CD28 (9); and (2…”
BackgroundHannani, D., Vétizou, M., Enot, D. P., Rusakiewicz, S., Chaput, N., Klatzmann, D., Desbois, M., Jacquelot, N., Vimond, N., Chouaïb, S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.28 · Cited by 135
Balogh, A., Persa, E., Bogdándi, E. N., Benedek, A., Hegyesi, H., Sáfrány, G., & Lumniczky, K. (2012) · Inflammation Research · doi:10.1007/s00011-012-0567-y · Cited by 133
“It was also suggested that increased cell surface expression of the CTLA4 antigen is also specific for activated Treg cells and is correlated with the immune suppressive function of Tregs [63–65].”
BackgroundHuman αβ and γδ T Cells in Skin Immunity and Disease
Cruz, M. S., Diamond, A., Russell, A., & Jameson, J. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01304 · Cited by 110
“Both CTLA-4 and IL-2RA are critical regulators of regulatory T cells (124, 138).”
BackgroundImmune evasion in acute myeloid leukemia: current concepts and future directions
Teague, R. M., & Kline, J. P. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-13 · Cited by 137
“Treg-mediated suppression of effector T cells is accomplished through diverse mechanisms that include competition for IL-2 [70], secretion of inhibitory cytokines, such as IL-10, IL-35 [71], and TGFβ [72], production of extra-cellular adenosine [73], and by altering the function of antigen presenting cells through the…”
T Regulatory Cells Control Susceptibility to Invasive Pneumococcal Pneumonia in Mice
Neill, D. R., Fernandes, V. E., Wisby, L., Haynes, A. R., Ferreira, D. M., Laher, A., Strickland, N., Gordon, S. B., Denny, P., Kadioglu, A., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002660 · Cited by 132
“Whilst these cells have differentiation requirements more similar to iTregs than nTregs, they share similar immunosuppressive qualities with nTregs, such as IL-10 production and CTLA-4 expression [35].”
InfluentialKhaja, A. S. S., Toor, S. M., El Salhat, H., Faour, I., Ul Haq, N., Ali, B. R., & Elkord, E. (2017) · Oncotarget · doi:10.18632/oncotarget.16565 · Cited by 121
Immune checkpoint blockade opens a new way to cancer immunotherapy
Sadreddini, S., Baradaran, B., Aghebati‐Maleki, A., Sadreddini, S., Shanehbandi, D., Fotouhi, A., & Maleki, L. A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27816 · Cited by 132
Type 1 Diabetes Mellitus: Cellular and Molecular Pathophysiology at A Glance.
Saberzadeh-Ardestani, B., Karamzadeh, R., Basiri, M., Hajizadeh‐Saffar, E., Farhadi, A., Shapiro, A. M. J., Tahamtani, Y., & Baharvand, H. (2018) · PubMed Central · doi:10.22074/cellj.2018.5513 · Cited by 132
“CTLA4 is crucial for proper repressive function of Tregs in mice (44).”
BackgroundHepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
Luo, X., He, X., Zhang, X., Zhao, X., Zhang, Y., Shi, Y., & Hua, S. (2024) · MedComm · doi:10.1002/mco2.474 · Cited by 135
Zhang, H., Wang, S., Huang, Y., Wang, H., Zhao, J., Gaskin, F., Yang, N., & Fu, S. M. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.02.001 · Cited by 130
“Proliferation was measured by flow cytometry [30].”
Muthu Raja, K. R., Rihova, L., Zahradova, L., Klincova, M., Penka, M., & Hajek, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047077 · Cited by 121
“granzymes (mediate lysis of conventional T cells) and CD95CD95L (induces apoptosis in conventional T cells) [11,12,13,14].”
BackgroundProspects for TIM3-Targeted Antitumor Immunotherapy
Ngiow, S. F., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1487 · Cited by 125
“© 2011 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from blockade and cell-intrinsic CTLA-4 deficiency have been shown to decrease the suppressive function of CD4þ Tregs (17).”
BackgroundReview: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Suarez-Almazor, M. E., Kim, S. T., Abdel‐Wahab, N., & Diab, A. K. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40043 · Cited by 134
“genetically deleted have dysfunctional Treg cells and T cell–mediated autoimmune diseases (37).”
BackgroundImmune checkpoint inhibitors in advanced non–small cell lung cancer
Assi, H. I., Kamphorst, A. O., Moukalled, N. M., & Ramalingam, S. S. (2018) · Cancer · doi:10.1002/cncr.31105 · Cited by 121
“During T-cell interactions with antigen-presenting cells (APCs), it has also been reported that CTLA-4 can reduce the expression of B7 molecules on APCs, resulting in APCs with attenuated priming ability.(16,17) Thus in animal models, different mechanisms have been proposed to explain how CTLA-4 checkpoint inhibition…”
BackgroundA Transendocytosis Model of CTLA-4 Function Predicts Its Suppressive Behavior on Regulatory T Cells
Hou, T. Z., Qureshi, O. S., Wang, C. J., Baker, J., Young, S. P., Walker, L. S. K., & Sansom, D. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401876 · Cited by 118
The Role of Regulatory T Cells in Cancer
Ha, T.-Y. (2009) · Immune Network · doi:10.4110/in.2009.9.6.209 · Cited by 131
“immunity, autoimmuniy and allergy (108).”
BackgroundChen, M., Yan, B., Lu, W., Chen, M., Yu, S., Yang, P., & Ann‐Lii, C. (2013) · International Journal of Cancer · doi:10.1002/ijc.28362 · Cited by 131
Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming
Matheu, M. P., Othy, S., Greenberg, M. L., Dong, T. X., Schuijs, M., Deswarte, K., Hammad, H., Lambrecht, B. N., Parker, I., & Cahalan, M. D. (2015) · Nature Communications · doi:10.1038/ncomms7219 · Cited by 116
JunB regulates homeostasis and suppressive functions of effector regulatory T cells
Koizumi, S.-I., Sasaki, D., Hsieh, T.-H., Taira, N., Arakaki, N., Yamasaki, S., Wang, K., Sarkar, S., Shirahata, H., Miyagi, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07735-4 · Cited by 114
Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer
Eckert, F., Schilbach, K., Klumpp, L., Bardoscia, L., Sezgın, E., Schwab, M. G., Zips, D., & Huber, S. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03018 · Cited by 130
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 132
“In the non-pathogenic setting, CTLA-4’s constitutive expression on regulatory T cells (T regs) serves a key role in immune tolerance, a regulatory mechanism that prevents the formation of self-reactive T cells that are capable of inducing autoimmune diseases in the host (56).”
BackgroundSignal pathways and precision therapy of small-cell lung cancer
Yuan, M., Zhao, Y., Arkenau, H., Lao, T., Chu, L., & Xu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01013-y · Cited by 131
De Novo Generation and Enhanced Suppression of Human CD4+CD25+ Regulatory T Cells by Retinoic Acid
Wang, J., Huizinga, T. W. J., & Toes, R. E. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901065 · Cited by 130
“CTLA-4 has recently been shown to control the in vivo function of murine CD4 Foxp3 Treg cells (48, 49) and to correlate with the acquisition of regulatory function of activated human T cells (41).”
BackgroundHTLV-1 modulates the frequency and phenotype of FoxP3+CD4+T cells in virus-infected individuals
Satou, Y., Utsunomiya, A., Tanabe, J., Nakagawa, M., Nosaka, K., & Matsuoka, M. (2012) · Retrovirology · doi:10.1186/1742-4690-9-46 · Cited by 130
“As an example of cell contact dependent suppression, expression of the immune suppressive molecule CTLA-4 on the cell surface inhibits the activation of surrounding neighboring T cells [26].”
BackgroundChinen, T., Volchkov, P. Y., Chervonsky, A. V., & Rudensky, A. Y. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20101235 · Cited by 120
“Recent studies have shown that T reg cells control activity of innate immune cells, including DCs and NK cells (Kim et al., 2007; Wing et al., 2008; Feuerer et al., 2009; Liu et al., 2009).”
ResultAntigen-specific regulatory T-cell responses to intestinal microbiota
Russler-Germain, E. V., Rengarajan, S., & Hsieh, C.-S. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.65 · Cited by 130
Tregs restrain dendritic cell autophagy to ameliorate autoimmunity
Alissafi, T., Banos, A., Boon, L., Sparwasser, T. D., Ghigo, A., Wing, K., Vassilopoulos, D., Boumpas, D. T., Chavakis, T., Cadwell, K., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92079 · Cited by 129
“CTLA4 is constitutively expressed by Foxp3+ Tregs and has been shown to be instrumental for Treg-mediated suppression (3, 7).”
BackgroundSelf-citationCTLA4 blockade elicits paraneoplastic neurological disease in a mouse model
Yshii, L., Gebauer, C., Pignolet, B., Mauré, E., Queriault, C., Pierau, M., Saito, H., 昇, 鈴., Brunner-Weinzierl, M. C., Bauer, J., et al. (2016) · Brain · doi:10.1093/brain/aww225 · Cited by 127
“Here again, CTLA4 maintains T cell tolerance by regulating the pathogenicity of autoantigen-specific T cells by both effector T cell autonomous effects and non-cell autonomous mechanisms, involving Treg cells (Wing et al., 2008; Ise et al., 2010).”
BackgroundMechanisms of Immune Tolerance in Leukemia and Lymphoma
Curran, E. K., Godfrey, J. K., & Kline, J. P. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.04.004 · Cited by 128
“CTLA-4 is also constitutively expressed on Treg cells [93], and is critical for their suppressive function [94].”
BackgroundZappasodi, R., Budhu, S., Hellmann, M. D., Postow, M. A., Şenbabaoğlu, Y., Manne, S., Gasmi, B., Liu, C., Zhong, H., Li, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.007 · Cited by 129
Zhang, Y., Du, X., Liu, M., Tang, F., Zhang, P., Ai, C., Fields, J. K., Sundberg, E. J., Latinovic, O., Devenport, M., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0184-1 · Cited by 127
Immunotherapy for cancer treatment during pregnancy
Borgers, J. S. W., Heimovaara, J. H., Cardonick, E., Dierickx, D., Lambertini, M., Haanen, J. B. A. G., & Amant, F. C. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00525-8 · Cited by 128
Metadata
- Authors
- Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S.
- Affiliations
- Tohoku University (JP)
- Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
- Corresponding author
- Wing, Kajsa
- Sakaguchi, Shimon
- Venue
- Science
- Published
- 2008-10-10
- Volume
- 322
- Issue
- 5899
- Pages
- 271-275
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2061071534
- Cited by
- 2,956
- References
- 25
- Citations by year
- 2026: 122 · 2025: 129 · 2024: 154 · 2023: 142 · 2022: 162 · 2021: 198 · 2020: 186 · 2019: 205 · 2018: 197 · 2017: 187 · 2016: 174 · 2015: 162 · 2014: 158 · 2013: 170 · 2012: 167
- FWCI
- 61.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4, Foxp3+ regulatory T cells, Treg suppressive function, lymphoproliferation, autoimmune disease, immunoglobulin E, antitumor immunity, dendritic cells, CD80, CD86, antigen presentation, immune tolerance
- MeSH terms
- Animals, Antigen-Presenting Cells, Autoimmune Diseases, Dendritic Cells, Female, Immunoglobulin E, Immunoglobulin G, Immune Tolerance, Leukemia, Lymphocyte Activation, Lymphocytes, Male, Mice, Inbred BALB C, Down-Regulation, Autoimmunity, Antigens, CD, B7-1 Antigen, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, B7-2 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.